03-07-01

UTILITY PANENT

APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: WM25

Page 1 of 2

Title: ELONGATED BIOPOLYMER STRUCTURE

CONTAINING FIBRIN

Express Mail Label No.: EL524824204US

| | APPLICATION ELEMENTS | ADDRESS TO: Assistant Commissioner for Patents | | | | | | |
|--|---|---|--|--|--|--|--|--|
| L.,, | (ENTORS: Vivos Dolmotto | Box Patent Application | | | | | | |
| linv | /ENTORS: Yves Delmotte | Washington, D.C. 20231 | | | | | | |
| 1. | Fee Transmittal Form (Submit an original, and a duplicate for fee processing) | 10. X Information Disclosure Statement (IDS)/PTO-1449 X Copies of IDS Citations | | | | | | |
| 2. | X Specification [Total Pages 56] | 11. Preliminary Amendment | | | | | | |
| 3. | X Drawing(s) (35 USC §113) [Total Pages (Fig. 1-14) 7] | 12. X Return Receipt Postcard (MPEP 503) | | | | | | |
| 4. | Signed Declaration [Total Pages] | 13. Small Entity Statement(s) | | | | | | |
| | a. Newly executed (original or copy) | Certified Copy of Priority Documents (s) | | | | | | |
| | b. Copy from a prior application (37 CFR §1.63(d)) | Sa. Cancel in the application original claimsbefore calculating the filing fee | | | | | | |
| | (Note Box 5 below) i | 5b. Amend the specification by inserting before the first line the sentence:This is a Continuation, | | | | | | |
| | Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b) | Divisional, Continuation-in-part, of application, filed | | | | | | |
| | | 15c. I hereby verify that the attached papers are a true copy of the | | | | | | |
| 5. | Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, | latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was | | | | | | |
| | from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the | signed. I hereby verify that the papers are a true copy of the latest signed prior application number, filed | | | | | | |
| | disclosure of the accompanying application and is hereby incorporated by reference therein. | aAnd further that all statements made herein of my own knowledge are true; and further that these statements were made with the | | | | | | |
| | knowledge that willful false statements and the like so made are | | | | | | | |
| 6. | Nucleotide and/or Amino Acid Sequence Submission | punishable by fine or imprisonment, or both, under Section 1001 Acid Sequence Submission of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any | | | | | | |
| a. | Computer Readable Copy Patent issuing thereon. | | | | | | | |
| b. c. | Paper Copy (identical to computer copy) Statement Verifiying identify of above copies | | | | | | | |
| 7. | Assignment Papers (cover sheet & document(s)) | | | | | | | |
| " | span (to a dodanom(o)) | 15d. Other: | | | | | | |
| | 27 OFD \$2 72/b) Statement | | | | | | | |
| 8. | 37 CFR §3.73(b) Statement Power of Attorney | | | | | | | |
| | English Translation Document | 15e. Other | | | | | | |
|] ^{3.} | 9. English Translation Document | | | | | | | |
| 16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: | | | | | | | | |
| | Continuation Divisional Continuation-in-part (CIP) of prior application No.: | | | | | | | |

UTILITY PAR ANT

APPLICATION TRANSMITTAL

Docket No.: WM202.00

Page 2 of 2

Title: ELONGATED BIOPOLYMER STRUCTURE

CONTAINING FIBRIN

(Under 37 C.F.R. §1.53(b))

Express Mail Label No.: EL524824204US

| CLAIMS | (1) FOR | (2) NUMBER | (3) NUMBER EXTRA | (4) RATE | (5) CALCULATIONS |
|--------|---|--------------------------------|---------------------|-------------|------------------|
| | TOTAL CLAIMS (37 CFR 1.16(b)) | 36-20 = | 16 | X \$ 18 = | \$288.00 |
| | INDEPENDENT CLAIMS (37 CFR 1.16(b)) | 5-3 = | 2 | X \$ 80 = | \$160.00 |
| | MULTIPLE DEPENDEN (37 CFR §1.16(d)) | T CLAIMS (if app | + \$ 270 = | \$ 0 | |
| | 5.50 X 2.70 | BASIC FEE (37 CFR §1.16(a)) | \$710.00 | | |
| | | | | TOTAL = | \$1158.00 |

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket WM252.00). (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. X Fees required under 37 CFR §1.16
- b. X Fees required under 37 CFR §1.17
- c. X Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME

Janice Guthrie, Reg. No. 35,170

SIGNATURE

DATE

March 6, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824204US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on March 6, 2001.

Mary Stickle